NASDAQ:BEAT - BioTelemetry Stock Price, Price Target & More

$34.00 +0.40 (+1.19 %)

(As of 04/24/2018 10:06 AM ET)

Previous Close$33.60

Today's Range$33.60 - $34.00

52-Week Range$23.30 - $39.20

Volume6,990 shs

Average Volume385,938 shs

Market Capitalization$1.13 billion

P/E Ratio34.64

Dividend YieldN/A

Beta0.86

About BioTelemetry (NASDAQ:BEAT)

BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:BEAT

CUSIPN/A

Webwww.gobio.com

Phone610-729-7000

Debt

Debt-to-Equity Ratio0.80%

Current Ratio1.77%

Quick Ratio1.66%

Price-To-Earnings

Trailing P/E Ratio34.64

Forward P/E Ratio26.77

P/E Growth1.7

Sales & Book Value

Annual Sales$286.78 million

Price / Sales3.88

Cash Flow$1.8438 per share

Price / Cash18.44

Book Value$7.70 per share

Price / Book4.42

Profitability

EPS (Most Recent Fiscal Year)$0.97

Net Income$-15,950,000.00

Net Margins-5.56%

Return on Equity14.54%

Return on Assets8.08%

Miscellaneous

Employees1,600

Outstanding Shares32,730,000

How to Become a New Pot Stock Millionaire

BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) announced its earnings results on Thursday, February, 22nd. The medical research company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.08. The medical research company earned $91.70 million during the quarter, compared to the consensus estimate of $88.33 million. BioTelemetry had a negative net margin of 5.56% and a positive return on equity of 14.54%. The business's quarterly revenue was up 69.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 earnings per share. View BioTelemetry's Earnings History.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for BioTelemetry.

What price target have analysts set for BEAT?

7 brokerages have issued 1-year target prices for BioTelemetry's stock. Their forecasts range from $37.00 to $50.00. On average, they expect BioTelemetry's stock price to reach $43.6667 in the next twelve months. View Analyst Ratings for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Some companies that are related to BioTelemetry include Indivior (INVVY), Integra lifesciences (IART), Premier (PINC), Hutchison China MediTech (HCM), Medidata Solutions (MDSO), LivaNova (LIVN), Orion (ORINY), Penumbra (PEN), Ablynx (ABLYF), Ablynx (ABLX), Haemonetics (HAE), DiaSorin (DIA), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO) and Healthequity (HQY).

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:

Mr. Joseph H. Capper, Chief Exec. Officer, Pres and Director (Age 54)
Mrs. Heather C. Getz CPA, Chief Financial Officer and Exec. VP (Age 43)
Mr. Peter F. Ferola, Sr. VP of Corp. Devel., Gen. Counsel & Sec. (Age 49)
Mr. Fred Broadway III, Sr. VP of Sales and Marketing (Age 48)
Dr. Peter R. Kowey M.D., FACC, FACP, FACCP, FCP, Medical Director and Chairman of Medical Advisory Board

Has BioTelemetry been receiving favorable news coverage?

News headlines about BEAT stock have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioTelemetry earned a news sentiment score of 0.19 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 45.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $33.60.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.13 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]

MarketBeat Community Rating for BioTelemetry (BEAT)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		205 (Vote Outperform)
Underperform Votes:		184 (Vote Underperform)
Total Votes:		389

MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.

BioTelemetry (NASDAQ:BEAT) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for BioTelemetry in the last 12 months. Their average twelve-month price target is $43.6667, suggesting that the stock has a possible upside of 28.43%. The high price target for BEAT is $50.00 and the low price target for BEAT is $37.00. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.71	2.71	2.71	2.75
Ratings Breakdown:	1 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 0 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$43.6667	$43.6667	$43.50	$43.50
Price Target Upside:	28.43% upside	32.12% upside	70.09% upside	47.71% upside

BioTelemetry (NASDAQ:BEAT) Consensus Price Target History

Price Target History for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ:BEAT) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/23/2018	Dougherty & Co	Reiterated Rating	Buy -> Buy	$40.00 -> $41.00	Low
10/26/2017	Raymond James	Initiated Coverage	Outperform	$37.00	N/A
10/23/2017	SunTrust Banks	Initiated Coverage	Buy	$41.00	N/A
9/15/2017	Off Wall Street	Initiated Coverage	Sell		Medium
8/10/2017	Sidoti	Reiterated Rating	Buy	$42.00 -> $49.00	Low
7/19/2017	Benchmark	Boost Price Target	Buy -> Buy	$38.00 -> $44.00	Low
7/14/2017	Lake Street Capital	Reiterated Rating	Buy	$35.00 -> $50.00	High
12/13/2016	Gabelli	Reiterated Rating	Buy		N/A

(Data available from 4/24/2016 forward)

BioTelemetry (NASDAQ:BEAT) Earnings History and Estimates Chart

Earnings by Quarter for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ:BEAT) Earnings Estimates

2018 EPS Consensus Estimate: $1.07

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.22	$0.24	$0.23
Q2 2018	1	$0.27	$0.27	$0.27
Q3 2018	1	$0.28	$0.28	$0.28
Q4 2018	1	$0.29	$0.29	$0.29
Q1 2019	1	$0.30	$0.30	$0.30
Q2 2019	1	$0.35	$0.35	$0.35
Q4 2019	1	$0.40	$0.40	$0.40

BioTelemetry (NASDAQ BEAT) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018		$0.24					N/A
2/22/2018	Q4 2017	$0.24	$0.32	$88.33 million	$91.70 million	View	Listen
11/7/2017	Q3 2017	$0.25	$0.16	$82.10 million	$81.02 million	View	N/A
8/8/2017	Q2 2017	$0.21	$0.23	$58.39 million	$58.10 million	View	Listen
5/3/2017	Q1 2017	$0.1430	$0.16	$55.11 million	$55.88 million	View	Listen
2/22/2017	Q4 2016	$0.18	$0.23	$53.75 million	$53.96 million	View	Listen
11/2/2016	Q316	$0.18	$0.21	$52.92 million	$53.10 million	View	N/A
8/2/2016	Q2	$0.17	$0.20	$50.27 million	$52.68 million	View	Listen
4/26/2016	Q1	$0.10	$0.20	$46.54 million	$48.60 million	View	Listen
2/17/2016	Q415	$0.11	$0.15	$45.89 million	$46.70 million	View	Listen
11/9/2015	Q3	$0.11	$0.13	$46.05 million	$43.49 million	View	N/A
8/6/2015	Q2	$0.09	$0.12	$45.75 million	$44.81 million	View	Listen
5/6/2015	Q115	$0.02	$0.06	$43.80 million	$43.40 million	View	Listen
2/19/2015	Q414	$0.06	$0.05	$43.40 million	$43.70 million	View	Listen
10/30/2014	Q214	$0.01	$0.06	$42.00 million	$43.00 million	View	Listen
7/31/2014	Q114	$0.01	$0.02	$40.95 million	$42.70 million	View	Listen
5/6/2014	Q413	($0.02)	($0.04)	$38.40 million	$37.16 million	View	Listen
2/26/2014	Q313	($0.04)	$0.05	$32.26 million	$33.10 million	View	Listen
11/5/2013		($0.05)	($0.12)	$32.79 million	$31.90 million	View	Listen
7/30/2013	Q2 2013		$0.02	$27.50 million	$32.10 million	View	Listen
4/22/2013	Q1 2013		($0.03)		$32.42 million	View	N/A
2/13/2013	Q4 2012		($0.09)	$26.80 million	$30.00 million	View	Listen
11/5/2012	Q312	($0.09)	($0.08)	$26.49 million	$27.00 million	View	N/A
8/8/2012		($0.04)	($0.01)			View	N/A
5/8/2012		($0.12)	($0.10)			View	N/A
2/22/2012		($0.13)	($0.04)			View	N/A
11/8/2011		($0.09)	($0.21)			View	N/A
8/8/2011		($0.06)	($0.05)			View	N/A
5/3/2011		($0.15)	($0.02)			View	N/A
2/17/2011		($0.16)	($0.13)			View	N/A
11/8/2010	Q3 2010	($0.05)	($0.25)			View	N/A
7/28/2010	Q2 2010	($0.10)	($0.09)			View	N/A
4/28/2010	Q1 2010	($0.18)	($0.13)			View	N/A
2/17/2010	Q4 2009	($0.12)	($0.24)			View	N/A
11/6/2009	Q3 2009	$0.03	($0.11)			View	N/A
8/5/2009	Q2 2009	$0.05	$0.06			View	N/A
4/30/2009	Q1 2009	$0.05	$0.04			View	N/A
2/17/2009	Q4 2008	$0.15	$0.16			View	N/A
10/30/2008	Q3 2008	$0.10	$0.11			View	N/A
7/22/2008	Q2 2008	$0.07	$0.08			View	N/A
4/29/2008	Q1 2008		$0.02			View	N/A

(Earnings results data provided by Zacks Investment Research)

BioTelemetry (NASDAQ:BEAT) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

BioTelemetry (NASDAQ BEAT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 87.29%

Insider Trading History for BioTelemetry (NASDAQ:BEAT)

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ BEAT) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2018	Fred Broadway	Insider	Sell	54,158	$34.17	$1,850,578.86	64,880
5/15/2017	Robert J. Rubin	Director	Sell	15,000	$28.14	$422,100.00
3/20/2017	Fred Broadway	SVP	Sell	3,429	$26.90	$92,240.10	25,420
2/27/2017	George Hrenko	SVP	Sell	126,043	$25.95	$3,270,815.85	23,172
2/21/2017	Fred Broadway	SVP	Sell	8,070	$24.81	$200,216.70	28,849
9/19/2016	George Hrenko	SVP	Sell	1,061	$18.50	$19,628.50	37,568
9/13/2016	Heather C Getz	CFO	Sell	5,866	$18.23	$106,937.18	44,293
9/13/2016	Joseph H Capper	Insider	Sell	26,847	$18.23	$489,420.81	189,838
9/13/2016	Peter Ferola	General Counsel	Sell	4,352	$18.23	$79,336.96	30,989
9/9/2016	Fred Broadway	SVP	Sell	3,146	$17.84	$56,124.64	37,886
9/8/2016	George Hrenko	SVP	Sell	3,491	$18.06	$63,047.46	42,500
9/8/2016	Heather C Getz	CFO	Sell	2,979	$18.10	$53,919.90	50,159
9/8/2016	Joseph H Capper	Insider	Sell	13,632	$18.10	$246,739.20	216,685
9/8/2016	Peter Ferola	General Counsel	Sell	2,210	$18.10	$40,001.00	28,847
9/7/2016	Daniel Wisniewski	SVP	Sell	9,225	$18.51	$170,754.75	38,672
9/7/2016	Heather C Getz	CFO	Sell	18,945	$18.52	$350,861.40	65,536
9/7/2016	Joseph H Capper	Insider	Sell	86,681	$18.52	$1,605,332.12	287,045
9/7/2016	Peter Ferola	General Counsel	Sell	14,053	$18.52	$260,261.56	26,637
9/6/2016	Fred Broadway	SVP	Sell	4,662	$18.28	$85,221.36	52,379
9/6/2016	Heather C Getz	CFO	Sell	6,686	$18.29	$122,286.94	65,536
9/6/2016	Joseph H Capper	CEO	Sell	30,595	$18.29	$559,582.55	287,045
9/6/2016	Peter Ferola	General Counsel	Sell	4,960	$18.29	$90,718.40	26,637
9/2/2016	Fred Broadway	SVP	Sell	4,466	$18.75	$83,737.50	52,379
9/2/2016	Heather C Getz	CFO	Sell	6,547	$18.75	$122,756.25	65,536
9/2/2016	Joseph H Capper	CEO	Sell	29,953	$18.75	$561,618.75	287,045
9/2/2016	Peter Ferola	General Counsel	Sell	4,856	$18.75	$91,050.00	26,637
9/1/2016	Fred Broadway	SVP	Sell	7,525	$19.25	$144,856.25	61,756
9/1/2016	Heather C Getz	CFO	Sell	10,408	$18.59	$193,484.72	78,721
9/1/2016	Joseph H Capper	Insider	Sell	47,622	$18.59	$885,292.98	347,373
9/1/2016	Peter Ferola	General Counsel	Sell	7,722	$18.59	$143,551.98	35,177
8/30/2016	Fred Broadway	SVP	Sell	12,121	$19.07	$231,147.47	71,719
8/30/2016	Heather C Getz	CFO	Sell	17,482	$19.07	$333,381.74	93,091
8/30/2016	Joseph H Capper	Insider	Sell	79,986	$19.07	$1,525,333.02	413,117
8/30/2016	Peter Ferola	General Counsel	Sell	12,970	$19.07	$247,337.90	45,838
8/25/2016	Fred Broadway	SVP	Sell	5,877	$19.16	$112,603.32	76,491
8/25/2016	Heather C Getz	CFO	Sell	8,477	$19.16	$162,419.32	99,973
8/25/2016	Joseph H Capper	Insider	Sell	38,785	$19.16	$743,120.60	450,606
8/25/2016	Peter Ferola	General Counsel	Sell	6,289	$19.16	$120,497.24	50,944
8/24/2016	George Hrenko	SVP	Sell	7,473	$20.11	$150,282.03	103,888
8/24/2016	Heather C Getz	CFO	Sell	8,778	$20.11	$176,525.58	120,945
8/24/2016	Joseph H Capper	CEO	Sell	40,160	$20.11	$807,617.60	546,559
8/24/2016	Peter Ferola	General Counsel	Sell	6,512	$20.11	$130,956.32	66,503
8/23/2016	George Hrenko	SVP	Sell	3,165	$20.67	$65,420.55	103,888
8/23/2016	Heather C Getz	CFO	Sell	3,717	$20.67	$76,830.39	120,945
8/23/2016	Joseph H Capper	CEO	Sell	17,008	$20.67	$351,555.36	546,559
8/23/2016	Peter Ferola	General Counsel	Sell	2,758	$20.67	$57,007.86	66,503
8/22/2016	George Hrenko	SVP	Sell	4,149	$20.85	$86,506.65	103,888
8/22/2016	Heather C Getz	CFO	Sell	4,874	$20.85	$101,622.90	120,945
8/22/2016	Joseph H Capper	CEO	Sell	22,298	$20.85	$464,913.30	546,559
8/22/2016	Peter Ferola	General Counsel	Sell	3,616	$20.85	$75,393.60	66,503
8/19/2016	Daniel Wisniewski	SVP	Sell	9,025	$20.96	$189,164.00	68,501
8/19/2016	Heather C Getz	CFO	Sell	9,026	$20.96	$189,184.96	125,819
8/19/2016	Joseph H Capper	Insider	Sell	9,049	$20.96	$189,667.04	568,857
8/19/2016	Peter Ferola	General Counsel	Sell	9,035	$20.96	$189,373.60	70,119
5/9/2014	Ronald Ahrens	Director	Buy	6,000	$7.37	$44,220.00	187,629
11/12/2013	Ronald Ahrens	Director	Buy	5,000	$11.73	$58,650.00	164,467
11/12/2012	Ronald A Ahrens	Director	Buy	15,000	$2.22	$33,300.00
9/5/2012	Joseph H Capper	CEO	Buy	23,540	$2.25	$52,965.00
8/31/2012	Joseph H Capper	CEO	Buy	2,600	$2.28	$5,928.00
8/29/2012	Joseph H Capper	CEO	Buy	10,800	$2.30	$24,840.00
8/28/2012	Joseph H Capper	CEO	Buy	1,300	$2.19	$2,847.00
8/27/2012	Joseph H Capper	CEO	Buy	1,600	$2.12	$3,392.00
8/23/2012	Joseph H Capper	CEO	Buy	9,600	$2.08	$19,968.00
8/20/2012	Joseph H Capper	CEO	Buy	14,160	$1.97	$27,895.20
8/17/2012	Joseph H Capper	CEO	Buy	9,800	$2.10	$20,580.00

(Data available from 1/1/2013 forward)

BioTelemetry (NASDAQ BEAT) News Headlines

Source:

Date	Headline
	BioTelemetry Inc (BEAT) to Post Q1 2018 Earnings of $0.24 Per Share, Dougherty & Co Forecasts www.americanbankingnews.com - April 24 at 7:50 AM
	BioTelemetry (BEAT) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - April 24 at 7:10 AM
	Comparing Acadia Healthcare (ACHC) and BioTelemetry (BEAT) www.americanbankingnews.com - April 22 at 1:36 AM
	Zacks: Brokerages Anticipate BioTelemetry Inc (BEAT) Will Announce Quarterly Sales of $91.63 Million www.americanbankingnews.com - April 21 at 2:52 AM
	Zacks: Analysts Expect BioTelemetry Inc (BEAT) Will Post Earnings of $0.27 Per Share www.americanbankingnews.com - April 19 at 3:10 PM
	BioTelemetry (BEAT) Upgraded by BidaskClub to "Buy" www.americanbankingnews.com - April 17 at 10:29 AM
	BioTelemetry (BEAT) Downgraded to Buy at BidaskClub www.americanbankingnews.com - April 16 at 12:03 PM
	BioTelemetry (BEAT) Now Covered by Analysts at Raymond James Financial www.americanbankingnews.com - April 4 at 7:30 PM
	Head-To-Head Contrast: BioTelemetry (BEAT) and AAC (AAC) www.americanbankingnews.com - April 4 at 3:21 PM
	Head to Head Analysis: BioTelemetry (BEAT) vs. Hanger (HNGR) www.americanbankingnews.com - April 4 at 3:21 PM
	BioTelemetry, Inc. (BEAT) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - April 4 at 1:47 PM
	$91.55 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter www.americanbankingnews.com - April 4 at 2:32 AM
	Contrasting Acadia Healthcare (ACHC) and BioTelemetry (BEAT) www.americanbankingnews.com - April 3 at 11:52 PM
	BioTelemetry, Inc. (BEAT) Expected to Post Earnings of $0.25 Per Share www.americanbankingnews.com - April 2 at 5:16 PM
	BioTelemetry (BEAT) Upgraded to "Buy" by BidaskClub www.americanbankingnews.com - March 26 at 5:58 PM
	Edited Transcript of BEAT earnings conference call or presentation 22-Feb-18 10:00pm GMT finance.yahoo.com - March 26 at 5:28 PM
	Commit To Buy BioTelemetry At $24, Earn 10.2% Annualized Using Options - Nasdaq www.nasdaq.com - March 24 at 8:41 AM
	BioTelemetry (BEAT) Downgraded to Hold at BidaskClub www.americanbankingnews.com - March 23 at 11:20 PM
	WellCare Health Plans (WCG) vs. BioTelemetry (BEAT) Critical Comparison www.americanbankingnews.com - March 23 at 8:52 AM
	BioTelemetry (BEAT) Lowered to C at TheStreet www.americanbankingnews.com - March 22 at 8:28 AM
	What Analysts Recommend for Amedisys and Peers in March 2018 finance.yahoo.com - March 19 at 8:10 AM
	SunTrust Banks Comments on BioTelemetry, Inc.'s Q1 2019 Earnings (BEAT) www.americanbankingnews.com - March 19 at 6:46 AM
	$91.40 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter www.americanbankingnews.com - March 18 at 4:25 AM
	This Morning's Technical Outlook on Medical Research Stocks -- Agilent Technologies, BioTelemetry, Accelerate ... - PR Newswire (press release) www.prnewswire.com - March 16 at 8:08 AM
	Fred Broadway Sells 54,158 Shares of BioTelemetry, Inc. (BEAT) Stock www.americanbankingnews.com - March 14 at 7:11 PM
	BioTelemetry (BEAT) Upgraded by BidaskClub to Buy www.americanbankingnews.com - March 10 at 7:10 PM
	BioTelemetry, Inc. (BEAT) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - March 10 at 3:25 PM
	Exploring BioTelemetry’s Segments finance.yahoo.com - March 6 at 5:47 PM
	A Look at BioTelemetry’s Financial Performance finance.yahoo.com - March 6 at 5:47 PM
	Millrace Asset Group Inc. Buys 41,100 Shares of BioTelemetry, Inc. (BEAT) www.americanbankingnews.com - March 5 at 12:52 PM
	BioTelemetry (BEAT) Downgraded by BidaskClub www.americanbankingnews.com - March 3 at 6:10 PM
	BioTelemetry Breaks Below 200-Day Moving Average - Notable for BEAT - Nasdaq www.nasdaq.com - March 2 at 8:06 AM
	Analysis: Positioning to Benefit within Bluerock Residential Growth REIT, National Presto Industries, Healthways ... - GlobeNewswire (press release) globenewswire.com - March 1 at 8:06 AM
	BioTelemetry, Inc. (BEAT) Expected to Post Quarterly Sales of $91.40 Million www.americanbankingnews.com - March 1 at 4:34 AM
	Equities Analysts Issue Forecasts for BioTelemetry, Inc.'s FY2020 Earnings (BEAT) www.americanbankingnews.com - February 28 at 4:30 PM
	BioTelemetry, Inc. (BEAT) Forecasted to Post Q1 2018 Earnings of $0.30 Per Share www.americanbankingnews.com - February 28 at 8:56 AM
	Equities Analysts Issue Forecasts for BioTelemetry, Inc.'s FY2019 Earnings (BEAT) www.americanbankingnews.com - February 27 at 3:02 PM
	Cortina Asset Management LLC Raises Holdings in BioTelemetry, Inc. (BEAT) www.americanbankingnews.com - February 27 at 1:40 PM
	Analysts Anticipate BioTelemetry, Inc. (BEAT) Will Announce Earnings of $0.21 Per Share www.americanbankingnews.com - February 27 at 1:24 PM
	BioTelemetry, Inc. Forecasted to Post FY2018 Earnings of $1.26 Per Share (BEAT) www.americanbankingnews.com - February 27 at 11:35 AM
	BioTelemetry Inc (BEAT) Files 10-K for the Fiscal Year Ended on December 31, 2017 finance.yahoo.com - February 27 at 8:08 AM
	BioTelemetry, Inc. (BEAT) Shares Bought by Comerica Bank www.americanbankingnews.com - February 25 at 5:10 AM
	BioTelemetry, Inc. (BEAT) Shares Bought by Columbia Partners L L C Investment Management www.americanbankingnews.com - February 24 at 4:20 PM
	BioTelemetry (BEAT) Price Target Increased to $41.00 by Analysts at Dougherty & Co www.americanbankingnews.com - February 23 at 6:14 PM
	BioTelemetry's (BEAT) CEO Joseph Capper on Q4 2017 Results - Earnings Call Transcript seekingalpha.com - February 23 at 6:07 PM
	BioTelemetry Q4 Earnings Preview - Benzinga www.benzinga.com - February 23 at 8:09 AM
	BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results ... - GlobeNewswire (press release) globenewswire.com - February 23 at 8:09 AM
	BioTelemetry reports 4Q loss finance.yahoo.com - February 23 at 8:09 AM
	BioTelemetry (BEAT) Announces Quarterly Earnings Results www.americanbankingnews.com - February 22 at 9:32 PM
	BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results finance.yahoo.com - February 22 at 5:44 PM

BioTelemetry (NASDAQ:BEAT) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

BioTelemetry (NASDAQ:BEAT) Income Statement, Balance Sheet and Cash Flow Statement

BioTelemetry (NASDAQ BEAT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff